(Total Views: 537)
Posted On: 11/03/2021 2:07:30 PM
Post# of 155819
Re: Evil Rabbit #109638
Check out the story on Greenwich Lifesciences, Inc (GLSI). End of 2020 they announced a good result in 2b study for treatment of TNBC and controlling spread. Stock went from about 4 bucks to 158.00 on one day. Current price is 36.29. As far as I can tell it's still not approved by FDA.
P/R
Greenwich LifeSciences Soars 426% as 5-Year Phase 2b Immunotherapy Data Shows 100% Survival in Breast Cancer Patients
MT Newswires - 1:13PM ET 12/09/2020 - Shares of Greenwich LifeSciences (GLSI) surged by more than 500% intraday after the company said Wednesday that final analysis of data from a Phase 2b trial of its therapy to treat breast cancer showed no recurrences in patients who have undergone surgery.
Analysis studying disease=free survival for patients treated with GP2 shows 100% survival following surgery and Herceptin treatment for five years, according to a statement.
The company is preparing to enter a Phase 3 study to treat a similar population of moderate to severe breast cancer patients.
Price: 31.22, Change: +26.02, Percent Change: +500.38
P/R
Greenwich LifeSciences Soars 426% as 5-Year Phase 2b Immunotherapy Data Shows 100% Survival in Breast Cancer Patients
MT Newswires - 1:13PM ET 12/09/2020 - Shares of Greenwich LifeSciences (GLSI) surged by more than 500% intraday after the company said Wednesday that final analysis of data from a Phase 2b trial of its therapy to treat breast cancer showed no recurrences in patients who have undergone surgery.
Analysis studying disease=free survival for patients treated with GP2 shows 100% survival following surgery and Herceptin treatment for five years, according to a statement.
The company is preparing to enter a Phase 3 study to treat a similar population of moderate to severe breast cancer patients.
Price: 31.22, Change: +26.02, Percent Change: +500.38
(4)
(0)
